1632118-69-4

Basic information

• Product Name: BAR 501
• Synonyms: BAR 501;BAR501, 98%, a potent and selective agonist of GPBAR1
• CAS NO: 1632118-69-4
• Molecular Formula: C26H46O3
• Molecular Weight: 406.64164
• EINECS: -0
• Mol File: 1632118-69-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 527.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.047±0.06 g/cm3(Predicted)
• PKA: 14.82±0.70(Predicted)
• CAS DataBase Reference: BAR 501(CAS DataBase Reference)
• NIST Chemistry Reference: BAR 501(1632118-69-4)
• EPA Substance Registry System: BAR 501(1632118-69-4)

Safety Data

• Hazardous Substances Data: 1632118-69-4(Hazardous Substances Data)

Usage

General Description

BAR 501 is a fungicide that contains the active ingredient prothioconazole, which belongs to the chemical class of triazoles. It is used to control a range of pathogens in various crops, including wheat, barley, and rye. The chemical works by inhibiting the biosynthesis of ergosterol, a vital component of fungal cell membranes, leading to the disruption of cell membrane integrity and ultimately the death of the fungus. BAR 501 is effective at controlling diseases such as leaf rust, septoria tritici, and tan spot in cereal crops, providing protection and promoting healthy plant growth. It is important to follow label instructions and safety precautions when using this chemical to minimize environmental impact and ensure proper application.

Upstream product

• 10452-65-0 methyl 3α-acetoxy-7-oxo-5β-cholan-24-oate 
• 4651-67-6 7-Ketolithocholic acid 
• 10538-59-7 7-ketolithocholic methyl ester 
• 462122-38-9 3α-hydroxy-6α-ethyl-7-keto-5β-cholanic acid methyl ester 
• 863239-59-2 3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-carboxylic acid methyl ester 
• 951694-73-8 methyl (4R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate 

Relevant articles and documents

Synthesis and characterization of new impurities in obeticholic acid

Novel and efficient synthetic strategies are developed for the first synthesis of two new impurities found in obeticholic acid. The synthetic routes to the impurities are designed without column purification using 4-nitrobenzoyl chloride as a selective pr

CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES

13073PTWO 56 ABSTRACT The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases. 5

Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors

Bile acids exert genomic and nongenomic effects by interacting with membrane G-protein-coupled receptors, including the bile acid receptor GP-BAR1, and nuclear receptors, such as the farnesoid X receptor (FXR). These receptors regulate overlapping metabolic functions; thus, GP-BAR1/FXR dual agonists, by enhancing the biological response, represent an innovative strategy for the treatment of enteroendocrine disorders. Here, we report the design, total synthesis, and in vitro/in vivo pharmacological evaluation of a new generation of dual bile acid receptor agonists, with the most potent compound, 19, showing promising pharmacological profiles. We show that compound 19 activates GP-BAR1, FXR, and FXR regulated genes in the liver, increases the intracellular concentration of cAMP, and stimulates the release of the potent insulinotropic hormone GLP-1, resulting in a promising drug candidate for the treatment of metabolic disorders. We also elucidate the binding mode of the most potent dual agonists in the two receptors through a series of computations providing the molecular basis for dual GP-BAR1/FXR agonism.